


Ombitasvir

Chemical Properties

CAS No. :	1258226-87-7
Formula:	C50H67N7O8
Molecular Weight:	894.11
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a
Targets(IC50)	HCV Protease
In vivo	Ombitasvir was evaluated in vivo in a 3-day monotherapy study in 12 HCV genotype 1-infected patients at 5, 25, 50, or 200 mg dosed once daily. All patients were HCV genotype 1a infected and were without preexisting resistant variants at baseline as determined by clonal sequencing. Decreases in HCV RNA up to 3.1 log ₁₀ IU/ml were observed. Resistance-associated variants at position 28, 30, or 93 in NS5A were detected in patient samples 48 hours after the first dose. Clonal sequencing analysis indicated that wild-type virus was largely suppressed by ombitasvir during 3-day monotherapy, and at doses higher than 5 mg, resistant variant M28V was also suppressed. Ombitasvir was well tolerated at all doses, and there were no serious or severe adverse events. These data support clinical development of ombitasvir in combination with inhibitors targeting HCV NS3/4A protease (ABT-450 with ritonavir) and HCV NS5B polymerase (ABT-333, dasabuvir) for the treatment of chronic HCV genotype 1 infection[1].
Animal Research	The patients in the ombitasvir dose groups were enrolled sequentially, and within each group, patients were randomized (2:1) to either ombitasvir or placebo and treated under nonfasting conditions for 3 days while confined to the study site. The 200-mg dose group received a different formulation with higher bioavailability. Patients who received at least one dose of ombitasvir or placebo were provided the option to receive treatment with pegIFN/RBV for approximately 48 weeks once treatment with ombitasvir was completed. HCV RNA was measured using the Roche COBAS TaqMan HCV Test v2.0 real-time reverse transcriptase PCR assay (with a lower limit of quantification of 25 IU/ml and a lower limit of detection of 10 IU/ml). The virologic response was assessed as HCV RNA decrease from baseline in log ₁₀ IU/ml[1].

Solubility Information

Solubility	DMSO: 166.7 mg/mL (186.44 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

A DRUG SCREENING EXPERT

In vivo Formulation	10% DMSO+90% Saline: < 10 mg/mL (11.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (11.18 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>
---------------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1184 mL	5.5922 mL	11.1843 mL
5 mM	0.2237 mL	1.1184 mL	2.2369 mL
10 mM	0.1118 mL	0.5592 mL	1.1184 mL
50 mM	0.0224 mL	0.1118 mL	0.2237 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Krishnan P, Beyer J, Mistry N, et al. in vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis c virus ns5a[J]. *Antimicrob Agents Chemother.* 2015 Feb;59(2):979-87.
- Zhao L, Sun X, Hou C, et al. CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription. *Cell Death & Disease.* 2024, 15(12): 896.
- Sun Y, Wu J, Shen B, et al. Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. *International Journal of Molecular Sciences.* 2025, 26(3): 1381.
- Keating, Gillian M . Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection[J]. *Drugs,* 2016, 76(12):1203-1211.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481